Companies: 10,795·Total market cap: $144.5T
89bio, Inc.

89bio, Inc.

ETNBNASDAQHealthcare
$14.84
+$0.00(+0.00%)
Market Cap$2.2B
P/E Ratio
52W High$15.06
52W Low$4.16

89bio, Inc. (ETNB) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

etnb · stock forecast · 15 analysts (3M) · FMP · updated Feb 6, 2026

Analyst Rating & Consensus

Based on 15 Wall Street analysts in the past 3 months

SellBuy

Buy

15 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
9
Hold
6
Sell
0
Strong Sell
0
Total: 15 · Buy rate: 60.0%

12-Month Price Target

High

$25.00

Consensus

$17.17

+15.7% upside

Low

$12.00

Median: $14.5 · Last Close: $14.84

The 89bio, Inc. (ETNB) analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month ETNB price target is $17.17, representing +15.7% upside from the current price of $14.84.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $17 (15.7%)

Consensus Target

$17.17

15.7% upside

High Target

$25

68.5%

Low Target

$12

-19.1%

Current Price

$14.84

as of today

Based on analyst price targets, the ETNB stock price prediction for the next 12 months ranges from $12 to $25. The consensus ETNB price forecast of $17.17 implies 15.7% upside from the current price of $14.84.

Short-Term Price Prediction

Ranging

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$14.830.09%

1-day model range: $14.82–$14.83. Peak: $14.83 (-0.09%).

Long-Term Stock Price Prediction

⚠️ Long-term projections are hidden until 252 trading days of history (IPO / limited listing). Short-term tab may still show model output.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

NEUTRAL

Based on 14 technical indicators

43%57%0%
6Buy
8Neutral
0Sell
RSI (14)62.5Neutral
MACDNEUTRAL

Refreshes daily from EOD close

Moving Averages · ETNB · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$14.83BUY
MA 10$14.81BUY
MA 20$14.81BUY
MA 50$0.00NEUTRAL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $ETNB · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$14.83BUY
EMA 10$14.82BUY
EMA 20$14.81BUY
EMA 50$0.00NEUTRAL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $ETNB · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Raymond James2025-09-19
Downgrade ↓
OutperformMarket Perform
HC Wainwright & Co.2025-09-19
Downgrade ↓
BuyNeutral
Wolfe Research2025-09-19
Downgrade ↓
OutperformPeer Perform
B of A Securities2025-08-25
Maintains
BuyBuy
RBC Capital2025-08-08
Maintains
Sector PerformSector Perform
HC Wainwright & Co.2025-02-28
Maintains
BuyBuy
UBS2025-01-31
Maintains
BuyBuy
HC Wainwright & Co.2025-01-21
Maintains
BuyBuy
Cantor Fitzgerald2025-01-02
Maintains
OverweightOverweight
HC Wainwright & Co.2024-11-11
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on 89bio, Inc. (ETNB) stock. Of the recent 89 rating actions, 2 were upgrades and 6 were downgrades. 15 analysts currently cover ETNB.

Analyst Recommendation Trends

Buy ratings101
Hold ratings03↑ +3
Sell ratings00

ETNB analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$3M

↓ 90.9% YoY

Revenue Next Year

$4M

↑ 22.4% YoY

EPS This Year

$-2.21

EPS Next Year

$-2.30

↑ 4.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ETNB EPS of $-2.21 for the current fiscal year, based on estimates from 5 analysts. The ETNB revenue forecast is $3M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ETNB stock forecast is supported by two independent data sources: analyst consensus ratings from 15 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ETNB price target is $17.17 (+15.7% upside), with an analyst consensus of Buy.

The ETNB short-term stock prediction for tomorrow is $14.83 (-0.09%).

89bio, Inc. trades on NASDAQ under the ticker ETNB. The ETNB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 60% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ETNB forecast · 8 questions

According to 15 Wall Street analysts, the average 12-month ETNB price target is $17.17, with a high forecast of $25.00 and a low of $12.00. The median price target is shown in the chart above when available. This implies +15.7% potential upside from the current price of $14.84.

ETNB price targetWhat is ETNB price targetETNB analyst price targetETNB 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.